Dexela releases new breast imaging workstation

TriMed Staff | | Health Imaging | Screening
Dexela, a developer of breast imaging technologies, has launched its DexTop breast imaging workstation.

London-based Dexela said its DexTop supports full-field digital mammography (FFDM) workflow, as well as breast tomosynthesis. It employs a 64-bit computing platform and graphics hardware, the company said. DexTop can access the large datasets used in tomosynthesis.

Dexela said its modular, web services-based architecture of the DexTop means that it can be deployed as a central base station in tandem with satellite reading workstations and web based control of radiologists’ work-lists.

The DexTop is CE marked for sale in the European Union and received FDA 510(k) approval in April.

TriMed Staff

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.